

## 2016 Annual General Meeting – Chairman’s Address to Shareholders

**Melbourne, Australia; 7 December 2016:**

Good afternoon. My name is Damien Lim, and I am the Chairman of Mach7 Technologies Limited. On behalf of the Company, I welcome you to our 2016 Annual General Meeting. I would like to take this opportunity to address shareholders on the Company’s activities and progress during the 2016 financial year, and our initiatives for the 2017 financial year.

The 2016 financial year was a significant year of progress for the Company, during which we completed the merger of 3D Medical and Mach7 Technologies. The merger has given us a global customer footprint with a market leading proprietary core business in our Mach7 Enterprise Imaging Platform.

During the year, we launched a number of key strategic initiatives, including marketing stand-alone clinical applications, rolling out a pay-per-use revenue model and introducing a cloud offering.

In addition, we continued to focus on strengthening our patent portfolio, signing on new customers, and increasing our sales capabilities through distribution arrangements with major industry players in UK and Europe.

In 2017, we will continue to focus on winning new customers, generating additional revenue streams and increasing our market share of the global enterprise imaging market. We are confident that our recently implemented product and strategic initiatives, and recent wins, are positive indicators that the Company is nearing profitability.

On behalf of the Company, I would like to take this opportunity to thank all shareholders, our employees, my fellow Directors and all our stakeholders for their continued support.

**- ENDS**

**About Mach7 Technologies:**

Mach7 Technologies (ASX:M7T) develops innovative enterprise imaging IT solutions that create a clear and complete view of the patient to inform diagnosis, reduce care delivery delays and costs, and improve patient outcomes. Mach7's award-winning enterprise imaging platform provides a vendor neutral foundation for unstructured data consolidation and communication to power interoperability and enables healthcare enterprises to build their best-of-breed clinical ecosystems. Mach7's sophisticated workflow tools, advanced [clinical viewing](#) and optimised [vendor neutral archiving](#) solutions unlock silos of legacy systems empowering healthcare providers to own, access and share patient data without boundaries. Visit [www.mach7t.com](http://www.mach7t.com)

Mach7's wholly-owned subsidiary, 3D Medical Pty Ltd, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical's innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. Visit [www.3dmedical.com.au](http://www.3dmedical.com.au)

**Contacts:**

Albert Liong  
CEO  
+1 650 743 0167 (U.S.)  
[albert.liong@mach7t.com](mailto:albert.liong@mach7t.com)

Jenni Pilcher  
CEO Australia, CFO  
+61 3 9646 2222 (Australia)  
[jenni.pilcher@mach7t.com](mailto:jenni.pilcher@mach7t.com)

Julia Vaughn  
Investor Relations (U.S.)  
+1 802 768 0143 (U.S.)  
[julia.vaughn@mach7t.com](mailto:julia.vaughn@mach7t.com)